Best to read the half-year report of the 27th Sept for the latest update. They're still waiting for approval from both Salv and Portage shareholders it would seem.
Yes exactly. Intensity's approach is quite different from other cancer drug approaches of the past. Intensity's management have long recognised that the traditional way of treating patents with chemotherapy i.e intravenously, has its limitations and delivers a low concentration of the drug to the tumour site, and with poor dispersion. So they're saying it's not the drug that's the problem, it's the way it's being delivered, and have found a way to deliver standard proven chemo drugs directly to the tumour, leaving healthy cells intact, whilst very importanly stimulating an immune response. So in a way it's a mixture of chemotherapy and immunotherapy.
Ed Mcdermott tweet:
"I really believe in Intensity’s management and their intratumoural drug. The team have already delivered a number of successful drugs and this could well be their biggest yet."
https://twitter.com/IntensityInc
Intensity is tweeting some interesting articles at the moment and quite regularly now. Looks like they could really be on to something. I hope FFWD take up the option to increase their stake. That would send out a very strong message about Intensity's progress.
I really hope Ffwd take up the options and invest further in Intensity. It will send a really strong signal that trial results to date are really promising. Well we only need to wait until the end of Sept to find out. Loads of other news could arrive from our other investments could arrive this month also. Very exciting times!
I'm inclined to agree that there will be a big sell off in Portage once the shares are transferred, as Salv investors take their profits, however in the medium term the Portage price will be determined initially by the outcome of Intensity Therapeutics, which will probably be the first of Portage's investees to return capital, all being well. If Intensity does reveal some trial results in the autumn, and those results are good, the Portage sp will seem low even without a sell off, givens Intensity's potential.
Nice gesture of Lorne's. He could have just donated cash to the charity but the fact that it's shares says as much about his confidence in the company as it does about his altruism.
Good on you Lorne.
"We believe the Warrant will be of interest to UK based institutional investors and the Company plans to present, with Intensity management, the results of the IT-01 study to date to interested parties over the Summer."
It's not clear from the above as to whether shareholders will be party to the above results to date or whether it will just be institutional investors. The phase 1/2a clinical trials are not due to complete until the end of 2020 so the information will be fairly limited at this stage. I guess a good gauge as to how well the trial is progressing will be whether FFWD take up the option to invest a further $5 m in Sept.
The sp is going to see-saw around because it is impossible to determine the NPV of all its investee companies. Only Vogogo is listed and so the market is assigning an arbitrary value based on 1. Net cash and 2. The book value of the investments. Until the investees are sold or IPO the guess work will continue.
Huge progress has been made with most of the investees and so the true value NPV should be higher than the market cap by now, but the market is pricing in the uncertainty factor until we see some hard figures.
Lorne has always said we need to be patient, and as long as the updates continue to be positive the sp is really immaterial at this stage even though it may seem frustrating at times.
I've been in Salv ever since I saw these two really inspiring videos at the MI show in 2016. Great company, great team behind it. Great cause to defeat cancer! OK the videos are old now but still worth watching.
https://www.youtube.com/watch?v=68V0KbSXM0s
https://www.youtube.com/watch?v=ER6rkQDq_yw
Vogogo up 10%.
up 8%. Let's hope we've sen the bottom now. Quiet day on the Share Chat!
Many thanks for your detailed research Seeingtom. The Mail article was very vague I must admit as to what CTC type system it was and on the face of it the Parsortix seemed to tick all the boxes from the information given.
There do seem to be several other CTC systems around but Angle appears to be steps ahead of the competition in terms of the recognition it is receiving from the major KOLs.
I've never had any problems buying FFWD on Selftrade either. Easy to use website. No probs peeps!
Extensive media coverage of Angle would not really serve any purpose at present as their route to market is defined by a sequence of milestones that need to be achieved first, rather than publicity.
They need FDA approval, KOL backed clinical and research data and commercial partners. Yes they are CE marked but FDA approval is crucial for complete validation of the Parsortix system.
MBC clinical data should be available in the Autumn followed by hopefully FDA approval next year.
http://www.dailymail.co.uk/health/article-6049477/new-blood-test-spare-men-prostate-cancer-months-gruelling-chemotherapy.html
I suspect the article refers to the Parsortix system.
Well don't melt in the Spanish heatwave Wadders, but if you do make sure you sell me your FFWD shares first won't you! lol.
Nice find again Wadders, you're the wizard of research! Must admit I'd pretty much written off Pulseflow through their lack of positive newsflow, so this is encouraging.
https://www.youtube.com/watch?v=HOBa0XXlixk
Have posted this already, but just in case you haven't seen it, it's well worth watching.
The RNS needs to be seen in a good light. The board would not consider increasing stakes in companies like Factom and Intensity unless they were pretty confident of their future success. If it also means that Leap is not sold that too is good news. It would be a shame to sell Leap right now with all the recent news about GVC.